A clinical investigator at Children’s Hospital of Los Angeles, Hisham Abdel-Azim, MD, MS, and colleagues, have completed a study where they engineered T-cells to identify and target multiple sites on acute lymphoblastic leukemia cells rather than just one. This...
Leukemia
Category
German Government Injects €2.45m to ‘Get to Root of Problem’ of Leukemia: Preliminary Stem Cell-based Research
The German Federal Ministry of Education and Research (BMBF), has transferred €2.45m to a research collaborative known as LeukoSyStem to “get to the root of the problem” of leukemia. With an emphasis on stem cell research and “the starting point of leukemia,” the...
SSM Health Cardinal Glennon Participates in Advanced Clinical Trials for Children with Leukemia
Physicians at SSM Health Cardinal Glennon are using genetic profiling for individual treatment of leukemia for better response to a child’s specific case. Focusing on the whole child, the provider has embraced advanced clinical trials to offer children with leukemia...
Early-Stage OT-82 Developed by Roswell Park Comprehensive Cancer Center & Shows Promise to Fight High-Risk Leukemia
OT-82, a preclinical stage drug candidate developed at Roswell Park Comprehensive Cancer Center (RPCCC) Buffalo, shows promise as a treatment to fight high-risk leukemia. Licensed for R&D and commercialization to OncoTartis, a biotech venture organized by RPCCC’s...
Fred Hutch Shows how CRISPR Hides Healthy Cells from Leukemia Drug
Fred Hutchinson Cancer Research Center preclinical researchers seek to marry CRISPR and immunotherapy to try and improve treatment for leukemia. Why? For years, doctors have been plagued by a lose-lose trade-off: a bull’s-eye for certain cancer-killing drugs also...
Developing Cells Being Hijacked in Childhood Leukemia
Although similarities exist between childhood and adult leukemias, evidence suggests that the cancers don't share the same genetic roots. New research hints that childhood leukemia may be able to hijack only young, developing cells—like those found in fetuses...
Norway-Based Developer of AXL Inhibitor-based Cancer Drug Inks Deal with Global Contract Development & Manufacturing Organization
An experimental drug developed out of Norway gains momentum including FDA Fast Track, and its maker, BerGenBio ASA, selected drug development and contract drug manufacturer Piramal Pharma The investigational candidate, bemcentinib, was recently designated by the U.S....
St. Jude Children’s Research Hospital Clinical Trial Results Reduce Rate of Relapse for Children with Acute Lymphoblastic Leukemia (ALL)
St. Jude Children’s Research Hospital concluded the Total Therapy Study 16 evidencing the ability to successfully reduce the rate of central nervous system (CNS) relapse to 1.8% for acute lymphoblastic leukemia (ALL) in children. The Problem: ALL Relapse Despite...
City of Hope Leads Phase II Clinical Trial for Efficacy & Safety of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center’s Alex Herrera, MD, leads a Phase II clinical trial assessing the efficacy and safety of ADCT-301 (camidanlumab tesirine) in patients with relapsed or refractory Hodgkin lymphoma (HL). Sponsored by Swiss emerging biotech ADC Therapeutics...
Researching Biomarkers in Pediatric ALL Patients to Prevent Cognitive Damage
Researchers at Rutgers Cancer Institute are looking at biomarkers in pediatric acute lymphoblastic leukemia patients to determine how to prevent neurocognitive impairment from standard treatment. Cancer treatments can cause permanent deterioration of brain functions...
University of Minnesota Developed Platform Moves to First-in-Human Clinical Trial for Leukemia
A designer molecule discovered at the University of Minnesota activates the patient’s own immune cells to attack cancer. Known as tri-specific natural killer engagers (TriKE™), they are a combination protein that bridges an immune cell and a tumor cell to drive tumor...
Chinese Researchers Safely Utilize CRISPR to Treat a Man’s Leukemia and HIV
Using CRISPR, Chinese researchers safely manipulated the DNA of a living patient in an effort to cure his disease. This is a major milestone in the field of gene editing since the same technology was used last year by a Chinese scientist to create the world’s first...
Washington University Medicine St. Louis: An Elite Investigative Hub for Acute Myeloid Leukemia
Investigators from Washington University Siteman Cancer Center at Barnes-Jewish Hospital and Washington University Medical Center in St. Louis, MO, have been awarded a $15 million grant to enable them to continue ongoing study the genetic changes that drive acute...
Rutgers Cancer Institute of New Jersey Secures Grants & Pursues T-Cell Acute Lymphoblastic Leukemia
Rutgers Cancer Institute of New Jersey received over $2 million in grants recently to study potential treatment targets for a rare and aggressive blood cancer called T-cell acute lymphoblastic leukemia (T-ALL). The recent grant awards were reported by Rutgers Cancer...
Dr. Wang Zhenyi: Chinese Leukemia Doctor with the Human Touch
Dr. Wang Zhenyi Chinese pathophysiologist, hematologist and a professor emeritus of Medicine and pathophysiology at the Shanghai Jiao Tong University. He is well known for discovering the cure for acute promyelocytic leukemia while working with Laurent Degos in...
Investigator Profile: Dr. Jennifer Woyach, Nationally-Recognized Expert on Chronic Lymphocytic Leukemia (CLL) Clinical Trials
OncLive interviews Jennifer A. Woyach, MD, on the current research and treatment spectrum for chronic lymphocytic leukemia (CLL). Dr. Woyach, an investigator with The James Ohio State University Comprehensive Cancer Center, is a nationally recognized CLL expert and...
Emory University Winship Cancer Center-Led Team Find Therapeutic Target to Combat Leukemia Cells
A research team led by Emory University School of Medicine, Winship Cancer Institute have found a way of preventing cancer cells from consuming amino acids, which form the building blocks of proteins and other biomolecules. In addition to consuming sugar at a fast...
AstraZeneca’s Phase 3 ELEVATE-TN Trial of Calquence for Chronic Lymphocytic Leukemia Meets Primary Endpoint at Interim Analysis
AstraZeneca reported the phase 3 ELEVATE-TN trial, evaluating Calquence (acalabrutinib) for patients with previously untreated chronic lymphocytic leukemia, met the primary endpoint early. This follows the positive results of the ASCEND trial, announced in May, which...
VCU Massey Cancer Center Identifies Novel Combo Drug Effective Against AML During Preclinicals
Scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the Journal of Cancer Research, could lead to new and improved treatments for...
UCSF-Led Study Evidences Delays in Leukemia Diagnosis Based on Economic Status & Gender
A new study showcased at ASCO evidences economic bias against low income, female leukemia patients. The study was led by Lena Winestone, MD, MSHP, of the Benioff Children’s Hospital at the University of California, San Francisco. The team capitalized on rich data...